Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: Assessment of correlation between clinical response and vaccine parameters

Cancer Immunology, Immunotherapy

Volumn 58, Issue 1, 2009, Pages 1-14

  Engell Noerregaard, Lotte ^a   Hansen, Troels Holz ^a   Andersen, Mads Hald ^a   Thor Straten, Per ^a   Svane, Inge Marie ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cancer; Dendritic cells; Immunotherapy; Malignant melanoma; Tumour vaccines

Indexed keywords

DENDRITIC CELL VACCINE; FLU MATRIX PROTEIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN; MATRIX PROTEIN; T LYMPHOCYTE ANTIGEN; TETANUS TOXOID; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER PATIENT; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL SUBPOPULATION; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG MECHANISM; DRUG MEGADOSE; ENZYME LINKED IMMUNOSPOT ASSAY; ERYTHEMA; HUMAN; IMMUNE RESPONSE; LOW DRUG DOSE; MELANOMA; PRIORITY JOURNAL; REVIEW; SKIN INDURATION; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; HUMANS; MELANOMA;

EID: 54849437711     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0568-4     Document Type: Review

References (80)

1. M Ahmadzadeh SA Rosenberg 2006 IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients Blood 107 2409 2414
2. Y Akiyama R Tanosaki N Inoue 2005 Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells J Transl Med 3 4
3. Andersen MH, Sorensen RB, Schrama D, Svane IM, Becker JC, thor Straten P (2008) Cancer treatment: the combination of vaccination with other therapies. Cancer Immunol Immunother (in press)
4. CM Anderson AC Buzaid SS Legha 1995 Systemic treatments for advanced cutaneous melanoma Oncology (Williston Park) 9 1149 1158
5. J Banchereau F Briere C Caux 2000 Immunobiology of dendritic cells Annu Rev Immunol 18 767 811
6. J Banchereau AK Palucka M Dhodapkar 2001 Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine Cancer Res 61 6451 6458
7. J Banchereau RM Steinman 1998 Dendritic cells and the control of immunity Nature 392 245 252
8. J Banchereau H Ueno M Dhodapkar 2005 Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon J Immunother 28 505 516
9. DK Banerjee MV Dhodapkar E Matayeva RM Steinman KM Dhodapkar 2006 Expansion of FOXP3 high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients Blood 108 2655 2661
10. I Bedrosian R Mick S Xu 2003 Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients J Clin Oncol 21 3826 3835
11. N Bercovici N Haicheur S Massicard 2008 Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients J Immunother 31 101 112
12. Berntsen A, Trepiakas R, Wenandy L et al (2008) Dendritic cell vaccination of patients with metastatic renal cell carcinoma, a phase I/II study. J Immunother (in press)
13. CM Britten C Gouttefangeas MJ Welters 2008 The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8(+) T lymphocytes by structural and functional assays Cancer Immunol Immunother 57 289 302
14. AE Chang BG Redman JR Whitfield 2002 A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer Clin Cancer Res 8 1021 1032
15. M Dauer B Obermaier J Herten 2003 Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors J Immunol 170 4069 4076
16. IJ de Vries WJ Lesterhuis NM Scharenborg 2003 Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients Clin Cancer Res 9 5091 5100
17. PT Di L Pilla I Capone 2006 Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors Cancer Res 66 4943 4951
18. R Dillman S Selvan P Schiltz 2004 Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis Cancer Biother Radiopharm 19 658 665
19. ME Dudley SA Rosenberg 2007 Adoptive cell transfer therapy Semin Oncol 34 524 531
20. A Escobar M Lopez A Serrano 2005 Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients Clin Exp Immunol 142 555 568
21. B Escudier T Dorval N Chaput 2005 Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial J Transl Med 3 10
22. DB Fearnley LF Whyte SA Carnoutsos AH Cook DN Hart 1999 Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation Blood 93 728 736
23. L Fong D Brockstedt C Benike L Wu EG Engleman 2001 Dendritic cells injected via different routes induce immunity in cancer patients J Immunol 166 4254 4259
24. DI Gabrilovich 2007 Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited Lancet Oncol 8 2 3
25. AV Giblin JM Thomas 2007 Incidence, mortality and survival in cutaneous melanoma J Plast Reconstr Aesthet Surg 60 32 40
26. E Gilboa 2007 DC-based cancer vaccines J Clin Invest 117 1195 1203
27. M Gilliet M Kleinhans E Lantelme D Schadendorf G Burg FO Nestle 2003 Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen Blood 102 36 42
28. A Grover GJ Kim G Lizee 2006 Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes Clin Cancer Res 12 5801 5808
29. Y He J Zhang Z Mi P Robbins LD Falo Jr 2005 Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity J Immunol 174 3808 3817
30. Hersey P, Halliday GM, Farrelly ML, Desilva C, Lett M, Menzies SW (2008) Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma. Cancer Immunol Immunother 57(7):1039-1051
31. P Hersey SW Menzies GM Halliday 2004 Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma Cancer Immunol Immunother 53 125 134
32. A Hoos G Parmiani K Hege 2007 A clinical development paradigm for cancer vaccines and related biologics J Immunother 30 1 15
33. S Janetzki KS Panageas L Ben-Porat 2008 Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI) Cancer Immunol Immunother 57 303 315
34. H Jonuleit A Giesecke-Tuettenberg T Tuting 2001 A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection Int J Cancer 93 243 251
35. H Jonuleit U Kuhn G Muller 1997 Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions Eur J Immunol 27 3135 3142
36. JA Kyte G Gaudernack 2006 Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells Cancer Immunol Immunother 55 1432 1442
37. JA Kyte L Mu S Aamdal 2006 Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA Cancer Gene Ther 13 905 918
38. R Lau F Wang G Jeffery 2001 Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma J Immunother 24 66 78
39. T Lesimple EM Neidhard V Vignard 2006 Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients Clin Cancer Res 12 7380 7388
40. GP Linette D Zhang FS Hodi 2005 Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity Clin Cancer Res 11 7692 7699
41. MT Lotze B Hellerstedt L Stolinski 1997 The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy Cancer J Sci Am 3 Suppl 1 S109 S114
42. B Ludewig K McCoy M Pericin 2001 Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells J Immunol 166 3678 3687
43. ME Lutsiak RT Semnani PR De SV Kashmiri J Schlom H Sabzevari 2005 Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood 105 2862 2868
44. A Mackensen B Herbst JL Chen 2000 Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells Int J Cancer 86 385 392
45. RB Mailliard A Wankowicz-Kalinska Q Cai 2004 Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity Cancer Res 64 5934 5937
46. AE Morelli AW Thomson 2003 Dendritic cells under the spell of prostaglandins Trends Immunol 24 108 111
47. MA Morse RE Coleman G Akabani N Niehaus D Coleman HK Lyerly 1999 Migration of human dendritic cells after injection in patients with metastatic malignancies Cancer Res 59 56 58
48. PJ Mosca AC Hobeika TM Clay 2000 A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment Blood 96 3499 3504
49. PJ Mosca AC Hobeika K Colling 2002 Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand J Leukoc Biol 72 546 553
50. H Nagayama K Sato M Morishita 2003 Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2 Melanoma Res 13 521 530
51. N Nakai J Asai E Ueda H Takenaka N Katoh S Kishimoto 2006 Vaccination of Japanese patients with advanced melanoma with peptide, tumor lysate or both peptide and tumor lysate-pulsed mature, monocyte-derived dendritic cells J Dermatol 33 462 472
52. FO Nestle S Alijagic M Gilliet 1998 Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nat Med 4 328 332
53. MG O'Rourke M Johnson C Lanagan 2003 Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine Cancer Immunol Immunother 52 387 395
54. MG O'Rourke MK Johnson CM Lanagan 2007 Dendritic cell immunotherapy for stage IV melanoma Melanoma Res 17 316 322
55. AK Palucka MV Dhodapkar S Paczesny 2003 Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma J Immunother 26 432 439
56. AK Palucka H Ueno J Connolly 2006 Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity J Immunother 29 545 557
57. MC Panelli J Wunderlich J Jeffries 2000 Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100 J Immunother 23 487 498
58. G Parmiani C Castelli L Pilla M Santinami MP Colombo L Rivoltini 2007 Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients Ann Oncol 18 226 232
59. AP Rapoport EA Stadtmauer N Aqui 2005 Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer Nat Med 11 1230 1237
60. C Reis e Sousa 2001 Dendritic cells as sensors of infection Immunity 14 495 498
61. A Ribas JA Glaspy Y Lee 2004 Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy J Immunother 27 354 367
62. R Ridolfi M Petrini L Fiammenghi 2006 Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients J Transl Med 4 36
63. N Romani D Reider M Heuer 1996 Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability J Immunol Methods 196 137 151
64. M Salcedo N Bercovici R Taylor 2006 Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate Cancer Immunol Immunother 55 819 829
65. F Saleh W Renno I Klepacek 2005 Melanoma immunotherapy: past, present, and future Curr Pharm Des 11 3461 3473
66. F Sallusto A Lanzavecchia 1994 Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha J Exp Med 179 1109 1118
67. E Scandella Y Men S Gillessen R Forster M Groettrup 2002 Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells Blood 100 1354 1361
68. D Schadendorf S Ugurel B Schuler-Thurner 2006 Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG Ann Oncol 17 563 570
69. M Schnurr P Galambos C Scholz 2001 Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines Cancer Res 61 6445 6450
70. B Schuler-Thurner ES Schultz TG Berger 2002 Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells J Exp Med 195 1279 1288
71. CL Slingluff Jr GR Petroni GV Yamshchikov 2003 Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells J Clin Oncol 21 4016 4026
72. M Smithers K O'Connell S MacFadyen 2003 Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen Cancer Immunol Immunother 52 41 52
73. A Snijders P Kalinski CM Hilkens ML Kapsenberg 1998 High-level IL-12 production by human dendritic cells requires two signals Int Immunol 10 1593 1598
74. Z Su J Dannull BK Yang 2005 Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer J Immunol 174 3798 3807
75. Svane IM, Pedersen AE, Nikolajsen K, Zocca M-B (2008) Alterations in p53 specific T-cells and other lymfocyte subsets in breast cancer patients during immunotherapy with p53-peptide loaded dendritic cells and low-dose interleukin-2. (Submitted)
76. A Testori J Richards E Whitman 2008 Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 study group J Clin Oncol 26 955 962
77. B Thurner I Haendle C Roder 1999 Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma J Exp Med 190 1669 1678
78. M Trakatelli M Toungouz D Blocklet 2006 A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients Cancer Immunol Immunother 55 469 474
79. R Trepiakas AE Pedersen Ö Met MH Hansen IM Svane 2008 Comparison of alpha-type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparation from cancer patients Vaccine 26 23 2824 2832
80. R Vilella D Benitez J Mila 2004 Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate Cancer Immunol Immunother 53 651 658